Course Catalog

Community Oncology Connections™: How Can We Optimize the Use of Oral SERDs in the Community Oncology Setting? Best Practices for HR+/HER2– Breast Cancer | Tennessee Oncology Practice Society

Virginia Kaklamani, MD, DSc; Denise Yardley, MD, GCRA

Medical Crossfire®: TKIs and ADCs in HER2-Mutant NSCLC – Which Class, Which Line?

December 4, 2026

Show Me the Data: Immunotherapy Across the Hepatobiliary Cancer Continuum—From Embolization-Eligible HCC to Advanced Biliary Tract Cancers

November 5, 2026

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Washington State Medical Oncology Society

Kamel Abou Hussein, MD; Yan Ji, MD, PhD

Community Oncology Connections™: Bridging Academic and Community Connections to Advance Precision and Targeted Care in NF1 Plexiform Neurofibromas | Rhode Island Oncology Society

Daniela A. Bota, MD, PhD; Kurt C. Demel, MD, MBA

Community Oncology Connections™: Bridging Academic and Community Connections to Advance Precision and Targeted Care in NF1 Plexiform Neurofibromas | Nevada Oncology Society

Amy E. Armstrong, MD; Phioanh “Leia” Nghiemphu, MD

Project ECHO®: Applying PD-L1 Testing in mTNBC: Making Sense of Biomarker-Driven Frontline Care

Tiffany A. Traina, MD, FASCO; Nour Abuhadra, MD; Francesca Gany, MD, MS; Hannah Y. Wen, MD, PhD

Show Me the Data™: HER2-Mutant NSCLC in Transition — Translating Evidence to Practice

October 26, 2026

Community Oncology Connections™: How Can We Optimize the Use of Oral SERDs in the Community Oncology Setting? Best Practices for HR+/HER2– Breast Cancer | Texas Society of Clinical Oncology

Ajit K. Bisen, MD, MBA; Virginia Kaklamani, MD, DSc

Join Us at The Pathology Meeting in Las Vegas

October 4-5, 2026

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma – North Carolina

Syma Iqbal, MD; Benjamin Scheier, MD

Une Vision d’Espoir: Lighting the Way in GA Management & Treatment

SriniVas R. Sadda, MD, FARVO; Hong-Uyen Hua, MD; Adrienne W. Scott, MD, FASRS

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma – Minnesota

Geoffrey Ku, MD; Jack W. Erter III, MD, MMHC

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | South Carolina Oncology Society

Kamel Abou Hussein, MD; Kate Baxstrom, MD

BURST CME™ Activity 3: Exploring Combination Strategies in HR+/HER2– MBC: Where Do Oral SERDs Fit In?

Erica L. Mayer, MD, MPH; Jason Aboudi Mouabbi, MD

Expert Illustrations & Commentaries™: The Science of Extended Durability

Talia Kaden, MD; Diana Do, MD

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma – West Virginia

Sunnie S. Kim, MD; Kellie D. Spector, MD

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Iowa Oncology Society

Aditya Bardia, MD, MPH, FASCO; Priya Kumar, MBBS, MS

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Empire State Hematology & Oncology Society

Aditya Bardia, MD, MPH, FASCO; Mohammad F. Ali, MD

Oncology Town Hall: From Evidence to Action—Applying KRAS-Targeted Advances in Solid Tumors

Rajwanth Veluswamy, MD, MSCR; Alison Schram, MD; Brian M. Wolpin, MD, MPH

Community Oncology Connections™: Immunotherapy Across the SCLC Continuum: Optimizing Treatment Pathways from Limited-Stage Through Relapsed Disease

Webinar Series

Integrating Motivational Interviewing Techniques to Overcome Barriers to the Use of a Long-Acting Injectable Agent in Patients With Schizophrenia

Gerald Maguire, MD; Jacob Hanaie, PharmD, APh, BCPP; Charles Nguyen, MD, DFAPA

PER Regional Psychiatry Series: Optimizing Treatment for Difficult-to-Treat Depression: The Role of Vagal Nerve Stimulation Therapy

Gus Alva, MD, DFAPA; Lara Shirikjian, DO

Project ECHO®: From Evidence to Action: Integrating New ADC Approaches to Optimize Treatment Sequencing in mTNBC

Tiffany A. Traina, MD, FASCO; Nour Abuhadra, MD; Joshua Z. Drago, MD, MS; Ya Haddy Sallah, MD, MPH

Annual Hematology Meeting Preceding the 68th ASH Annual Meeting and Exposition

December 11, 2026

Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Kentucky

Lori A. Leslie, MD; Sushil Bhardwaj, MD, FACP

Cases & Conversations: Real-World Insights on the Diagnosis and Management of Cold Agglutinin Disease

September 2, 2026

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Rhode Island Oncology Society

Aditya Bardia, MD, MPH, FASCO; Benjamin Scheier, MD

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Arkansas Association of Cancer Professionals

Kamel Abou Hussein, MD; Yelda Nouri, MD

The ADC Revolution in Metastatic Breast Cancer: Redefining Treatment Selection and Sequencing

Seth A. Wander, MD, PhD; Reshma L. Mahtani, DO; Shanu Modi, MD; Joyce O’Shaughnessy, MD

𝘔𝘌𝘛 Alterations in NSCLC: Applying Diagnostic Advances and Targeted Therapies in a New Era of Treatment

Jonathan Goldman, MD; Sanja Dacic, MD, PhD; Deborah Doroshow, MD, PhD; Anne S. Tsao, MD, MBA

Advancing Targeted Therapy in HR+/HER2– Metastatic Breast Cancer: Integrating Next-Generation Endocrine and PAM-Pathway Strategies Into Practice

Joyce O’Shaughnessy, MD; Sarat Chandarlapaty, MD, PhD; Mitchell Elliott, MD, FRCPC; Seth A. Wander, ...

27th Annual International Lung Cancer Congress®

Roy S. Herbst, MD, PhD; Sandip Patel, MD, FASCO; Heather A. Wakelee, MD, FASCO

Evaluating Clinical Trials in Retinal Disease: Essentials for Eyecare Professionals

Medical Crossfire®: BPDCN in 2026—Expert Perspectives on Diagnosis, Frontline Therapy, and the Evolving CD123-Directed Pipeline

Andrew A. Lane, MD, PhD; Marlise Luskin, MD, MSCE; Kendra Sweet, MD

OncoBytes Microlearning Pathways: New Directions in Triple-Negative Breast Cancer – Practice-Ready Updates and Expert Insights Into Recent Therapeutic Breakthroughs – Nursing (Part 2)

OncoBytes Microlearning Pathways: New Directions in Triple-Negative Breast Cancer – Practice-Ready Updates and Expert Insights Into Recent Therapeutic Breakthroughs – Nursing (Part 1)

William J. Gradishar, MD, FASCO, FACP; Kamel Abou Hussein, MD

Introducing Novel Treatment Paradigms for Metastatic TNBC

Aditya Bardia, MD, MPH, FASCO; Alexis LeVee, MD

Key Considerations for Health Equity and Patient-Centered Care in TNBC

Aditya Bardia, MD, MPH, FASCO; Kathryn E. Post, PhD, ANP-BC

Current Approaches and Future Directions for Early-Stage TNBC

Nour Abuhadra, MD; Antonio Giordano, MD, PhD

From Trials to the Clinic ‒ Incorporating New Advances in Metastatic TNBC

William J. Gradishar, MD, FASCO, FACP; Kamel Abou Hussein, MD

Rapid Reviews in Retina™: 2026 Bimonthly Updates: Part Two — Safety

Hong-Uyen Hua, MD

25th Annual International Congress on the Future of Breast Cancer® West

Sara A. Hurvitz, MD, FACP; Joyce O’Shaughnessy, MD

Clinical Consultations: Comprehensive Management of Obesity as a Chronic Disease: New and Emerging Strategies

Fatima Cody Stanford, MD, MPH, MPA, MBA, MACP, FAAP, FAHA, FAMWA, FTOS; Robert Busch, MD

“D” is for Diagnosis™: Seeking the Cause of Abdominal Pain

Brendan McGuire, MD, MS; Herbert Bonkovsky, MD

Expert Illustrations & Commentaries™: Outlining the Role of BTK inhibitors in Multiple Sclerosis

Stephen Krieger, MD, FAAN; Enrique Alvarez, MD, PhD

Optimizing NSCLC Readiness in the Era of TROP2-Targeted ADCs: Frontline Combinations, CNS Disease, and Toxicity Differentiation

Solange Peters, MD, PhD; Myung-Ju Ahn, MD, PhD; Benjamin P. Levy, MD; Stephanie McDonald, FNP-BC, AO...

Advancing Access to High-Quality, Biomarker-Guided Care for All Patients With mNSCLC

Narjust Florez, MD, FASCO; Darren Luon, PharmD, BCOP; Dipesh Uprety, MD; Colton Zwart PharmD, BCOP